15.07.2010 • News

Novartis in $175 Million Gender Bias Settlement

Novartis has agreed to pay $175 million to settle a class-action lawsuit accusing the Swiss drugmaker of discriminating against 5,600 current and former female employees.

The settlement was announced less than two months after a Manhattan jury ordered Novartis to pay $250 million in punitive damages, after a six-week trial. That jury concluded the company's U.S. unit, Novartis Pharmaceuticals, engaged in a pattern of discrimination between 2002 and 2007.

Lawyers for the plaintiffs said it was the largest U.S. gender discrimination case ever to go to trial. In a joint statement with the plaintiffs' lawyers, Novartis said it will pay $152.5 million to eligible class members and pay an additional $22.5 million to improve companywide complaint processes, oversight and performance assessment.

The settlement requires court approval. U.S. District Judge Colleen McMahon scheduled a Nov. 19 hearing to consider whether to approve it.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.